|  |  |  |  | Univariate | Multivariate | ||
---|---|---|---|---|---|---|---|---|
 | No. of patients | Follow up (years) | No. of events | Rate | HR | p | HR (95% CI) | p-value |
Total | 3279 | 6815 | 135 | 1.98 | Â | Â | Â | Â |
Sex | ||||||||
Male | 2307 | 4883 | 100 | 2.05 | Â | Â | Â | Â |
Female | 972 | 1932 | 35 | 1.81 | 0.88 | 0.510 | 0.77 (0.52, 1.14) | 0.198 |
Age at entry of TAHOD (years) | ||||||||
< = 30 | 1103 | 2203 | 56 | 2.54 | Â | Â | Â | Â |
31~40 | 1401 | 2944 | 60 | 2.04 | 0.81 | 0.249 | 0.80 (0.56, 1.16) | 0.237 |
41+ | 775 | 1668 | 19 | 1.14 | 0.45 | 0.003 | 0.47 (0.28, 0.79) | 0.005 |
Reported mode of infection | ||||||||
Heterosexual contact | 2288 | 4896 | 102 | 2.08 | Â | Â | Â | Â |
Homosexual contact | 614 | 1243 | 16 | 1.29 | 0.62 | 0.074 | 1.29 (0.74, 2.23) | 0.367 |
Injecting drug use | 132 | 260 | 11 | 4.23 | 2.03 | 0.026 | 1.03 (0.54, 1.97) | 0.917 |
Blood products | 120 | 197 | 0 | 0.00 | --- | --- | --- | --- |
Other/unknown | 125 | 219 | 6 | 2.74 | 1.29 | 0.544 | 0.94 (0.41, 2.15) | 0.877 |
CDC classification for HIV infection * | ||||||||
Category A | 1747 | 3497 | 48 | 1.37 | Â | Â | Â | Â |
Category B | 622 | 1158 | 39 | 3.37 | 2.42 | <0.001 | 1.33 (0.86, 2.05) | 0.203 |
Category C | 1020 | 2160 | 48 | 2.22 | 1.62 | 0.017 | 1.37 (0.89, 2.10) | 0.150 |
CD4 count (cells/μL) * | ||||||||
< = 50 | 313 | 251 | 27 | 10.74 | Â | Â | Â | Â |
51–100 | 312 | 222 | 15 | 6.74 | 0.64 | 0.162 | 0.69 (0.36, 1.29) | 0.243 |
101–200 | 928 | 842 | 30 | 3.56 | 0.34 | <0.001 | 0.41 (0.24, 0.69) | 0.001 |
201–300 | 1224 | 1250 | 23 | 1.84 | 0.17 | <0.001 | 0.21 (0.12, 0.37) | <0.001 |
301+ | 2225 | 4197 | 30 | 0.71 | 0.07 | <0.001 | 0.08 (0.05, 0.14) | <0.001 |
Not tested | 68 | 53 | 10 | 18.98 | 1.83 | 0.106 | 1.02 (0.48, 2.15) | 0.969 |
Prior TB diagnosis | ||||||||
No | 2562 | 5254 | 94 | 1.79 | Â | Â | Â | Â |
Yes | 717 | 1561 | 41 | 2.63 | 1.47 | 0.038 | 1.08 (0.74, 1.59) | 0.684 |
Antiretroviral treatment * | ||||||||
No treatment | 830 | 985 | 40 | 4.06 | Â | Â | Â | Â |
Treated, 0~90 days | 453 | 83 | 14 | 16.91 | 4.01 | <0.001 | 2.52 (1.31, 4.84) | 0.006 |
Treated, 91–180 days | 674 | 147 | 9 | 6.11 | 1.45 | 0.328 | 0.96 (0.45, 2.04) | 0.909 |
Treated, 181–360 days | 1017 | 414 | 5 | 1.21 | 0.30 | 0.013 | 0.24 (0.09, 0.62) | 0.003 |
Treated 361+ days | 2452 | 5186 | 57 | 1.29 | 0.30 | <0.001 | 0.40 (0.26, 0.61) | <0.001 |
Country of TB burden | ||||||||
High | 1990 | 3644 | 115 | 3.16 | Â | Â | Â | Â |
Low/intermediate | 1289 | 3171 | 20 | 0.63 | 0.21 | <0.001 | 0.28 (0.17, 0.45) | <0.001 |